RxDoctor Payments Data

Lauren Spiegel, MD

Neurology · Morgan Hill, CANPI 1164840963

Payments from drug & device makers

$28,088in general payments, 2019–2025

Across 702 payments — averaging $40.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Eisai Inc.$3K
  • Teva Pharmaceuticals USA, Inc.$2K
  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$1K
  • SK Life Science, Inc.$1K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$2,88810%
  • Speaking & faculty fees$1270%
  • Grants$4,68817%
  • Travel & lodging$1,2024%
  • Food & beverage$18,97168%
  • Education$2121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)37$7,294
Eisai Inc.13$3,266
Teva Pharmaceuticals USA, Inc.68$2,411
AbbVie(2 entities)73$1,551
Neurocrine Biosciences, Inc.37$1,341
SK Life Science, Inc.52$1,130
Boston Scientific15$1,113
MDD US Operations, LLC24$882
AstraZeneca(2 entities)27$724
Acorda Therapeutics, Inc27$603
Pfizer21$498
UCB, Inc.20$466
Jazz Pharmaceuticals Inc.18$459
Biogen17$437
Argenx US, Inc.13$385
Kyowa Kirin, Inc.12$369
Noctrix Health, Inc.1$349
Lundbeck LLC18$290
Lilly USA, LLC11$288
Impel Pharmaceuticals Inc.20$264
Sunovion Pharmaceuticals Inc.14$262
Otsuka America Pharmaceutical, Inc.11$259
Acadia Pharmaceuticals Inc9$233
Biohaven Pharmaceuticals, Inc.19$225
Sumitomo Pharma America, Inc.10$213
Amneal Pharmaceuticals LLC8$196
Merz Pharmaceuticals, LLC7$169
Johnson & Johnson(2 entities)5$162
Biohaven Pharmaceutical Holding Company Ltd.17$156
GE HealthCare5$147
ANI Pharmaceuticals, Inc.6$136
Neurelis, Inc.4$133
Si-bone, Inc.1$129
Genentech USA, Inc.5$128
Octapharma USA, Inc.4$122
Corium, LLC5$119
Avanir Pharmaceuticals, Inc.5$105
Adamas Pharmaceuticals, Inc.4$82
CSL Behring3$76
Axsome Therapeutics, Inc.3$75
GRT US Holding, Inc.2$69
Vanda Pharmaceuticals Inc.2$69
Greenwich Biosciences, Inc.3$65
TG Therapeutics, Inc.2$62
Grifols USA, LLC2$58
Banner Life Sciences, LLC2$52
Ipsen Biopharmaceuticals, Inc2$50
Amgen2$45
Mallinckrodt Hospital Products Inc.2$44
Tris Pharma Inc2$43
Avion Pharmaceuticals2$37
Life Molecular Imaging Ltd1$33
Bridgebio Pharma, Inc.1$32
Averitas Pharma Inc.1$30
EMD Serono, Inc.1$29
Catalyst Pharmaceuticals, Inc.1$23
Bristol Myers Squibb1$22
Arbor Pharmaceuticals, Inc.1$22
Azurity Pharmaceuticals, Inc.1$20
Ultragenyx Pharmaceutical Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,088 in reported general payments places this provider in the 80th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$461,277
Medicare patients
747
Services billed
34,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4632$239,341
IngrezzaValbenazine Tosylate18$197,957
NuplazidPimavanserin Tartrate24$118,729
RytaryCarbidopa/Levodopa27$70,068
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$64,288
NeuproRotigotine35$60,800
CopaxoneGlatiramer Acetate11$60,359
NuedextaDextromethorphan Hbr/Quinidine24$56,999
Carbidopa-Levodopa ErCarbidopa/Levodopa274$27,474
Rivastigmine72$22,503
Glatiramer Acetate13$20,281
MyrbetriqMirabegron27$16,305
Carbidopa-LevodopaCarbidopa/Levodopa227$12,179
Donepezil Hcl694$11,696
Memantine Hcl295$11,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$58$239,34132 claims
Neurocrine Biosciences, Inc.Ingrezza$1,341$197,95718 claims
Acadia Pharmaceuticals IncNuplazid$233$118,72924 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$196$73,23663 claims
UCB, Inc.Neupro$466$60,80035 claims
Teva Pharmaceuticals USA, Inc.Copaxone$2,411$60,35911 claims
Avanir Pharmaceuticals, Inc.Nuedexta$105$56,99924 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,996 neurology providers in California.

Other neurology in Morgan Hill

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →